Our research team (JCRI-ABTS) at US Medical Innovations is using
Cold Atmospheric Plasma to selectively Target Cancer Cells and
Disrupt the Cell’s ability to Reproduce and Survive
What is Canady HeliosTM Cold Plasma?
Canady Helios Cold Plasma (CHCP) is a non-thermal process that according to JCRI/ABTS Research, triggers chemical-molecular changes in cancer cells leading to apoptosis (cell death), while normal cells are left unharmed.
The Cold Plasma Beam introduces electronically charged particles, Reactive Oxygen Species (ROS) and Reactive Nitrogen Species (RNS) to the Plasma Treatment Electrical Field (PTEF).1
A Multi-Disciplinary Treatment Process
A Typical Treatment Process
The Canady Cold Plasma Helios Flexible EndoProbe™
The Next Generation of Endo-Oncology Surgery
Procedure for Endoscopic Mucosal Resection Secondary to Esophageal Cancer
STEP 1
Relieve acute obstruction with Canady Hybrid Plasma™
STEP 2
Place stent, if indicated
STEP 3
Ablate remaining tumor with Canady Hybrid Plasma™
STEP 4
Remove stent and ablate remaining soft tissue with Canady Helios™ Cold Plasma
STEP 5
Multi-Disciplinary Treatment Follow-up Process (Chemo/Radiation/Targeted-Immunotherapy)
The Canady Cold Plasma Helios Flexible EndoProbe™
The Next Generation of Endo-Oncology Surgery
Procedure for Endoscopic Mucosal Resection Secondary to Esophageal Cancer
STEP 2
Relieve acute obstruction with Canady Hybrid Plasma™
STEP 3
Ablate remaining tumor with Canady Hybrid Plasma™
STEP 5
Multi-Disciplinary Treatment Follow-up Process (Chemo/Radiation)
STEP 1
Place stent, if indicated
STEP 4
Remove stent and ablate remaining soft tissue with Canady Helios™ Cold Plasma
The Canady Cold Plasma Helios Flexible EndoProbe™
The Next Generation of Endo-Oncology Surgery
Procedure for Endoscopic Mucosal Resection Secondary to Esophageal Cancer
STEP 1
Relieve acute obstruction with Canady Hybrid Plasma™
STEP 2
Place stent, if indicated
STEP 3
Ablate remaining tumor with Canady Hybrid Plasma™
STEP 4
Remove stent and ablate remaining soft tissue with Canady Helios™ Cold Plasma
STEP 5
Multi-Disciplinary Treatment Follow-up Process (Chemo/Radiation)
Safe – No Side Effects
The pioneering JCRI/ABTS Research proves when used intraoperatively (during your surgery), this low-temperature plasma treatment selectively targets cancer cells without damaging healthy surrounding tissue.1
There is no hair loss or other side effects.
CHCP may be very effective
in treating Solid Tumor Cancers
Based on JCRI/ABTS Research, spraying CHCP in the surgical margins during your cancer surgery may reduce the chance of local recurrence and may improve your chance of survival.1-7
1. The First Cold Atmospheric Plasma Phase I Clinical Trial for the Treatment of Advanced Solid Tumors: A Novel Treatment Arm for Cancer
Cancers 2023, 15(14), 3688; – https://doi.org/10.3390/cancers15143688
2. Canady Cold Helios Plasma Reduces Soft Tissue Sarcoma Viability by Inhibiting Proliferation, Disrupting Cell Cycle, and Inducing Apoptosis: A Preliminary Report
Molecules 2022, 27(13), 4168; – https://doi.org/10.3390/molecules27134168
3. The Granger Causal Effects of Canady Helios Cold Plasma on the Inhibition of Breast Cancer Cell Proliferation
Appl. Sci. 2022, 12(9), 4622; https://doi.org/10.3390/app12094622
4. BCL2A1 Regulates Canady Helios Cold Plasma-induced Cell Death in Triple-Negative Breast Cancer
Scientific Reports volume 12, Article number: 4038 (2022) – https://www.nature.com/articles/s41598-022-07027-4
5. Canady Helios Cold Plasma Induces Breast Cancer Cell Death by Oxidation of Histone mRNA
Int. J. Mol. Sci. 2021, 22(17), 9578; – https://doi.org/10.3390/ijms22179578
6. The synergistic effect of Canady Helios cold atmospheric plasma and a FOLFIRINOX regimen for the treatment of cholangiocarcinoma in vitro
Scientific Reports volume 11, Article number: 8967 (2021) – https://www.nature.com/articles/s41598-021-88451
7. Canady cold plasma conversion system treatment: An effective inhibitor of cell viability in breast cancer molecular subtypes
Clinical Plasma Medicine (Elsevier) Volumes 19–20, September–December 2020, 100109. – https://doi.org/10.1016/j.cpme.2020.100109